Table 1 Clinical parameters of patients with SPECT/CT-follow up after COVID-19 associated PE
COVID-19 disease | SPECT/CT-follow up | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
№ | Gender | Age | Respiratory support | Specific COVID therapy | COVID rehab | Severity of PE [13] | Thrombolysis | Pulmonary thrombus localization | Quanadli- score | Remaining perfusion defects | New perfusion defects | Persistent pulmonary infiltrates | Duration of OAC treatment | Type of OAC | OAC-related bleeding | VTE recurrence | Clinical recovery |
1 | male | 33 | high-flow oxygen | steroid, convalescent plasma | no | low-risk | no | segmental | 15 | no | no | no | 6 months | DOAC | no | no | full |
2 | male | 33 | ECMO | steroid, convalescent plasma | no | low-risk | no | segmental | 3 | no | no | no | 3 months | DOAC | no | no | full |
3 | male | 57 | oxygen | steroid | yes | low-risk | no | segmental | 9 | no | no | no | 6 months | DOAC | no | no | partial |
4 | male | 54 | NIV | steroid, convalescent plasma | no | high-risk | yes | central | 32 | no | no | yes | 6 months | DOAC | no | no | partial |
5 | male | 61 | IV | steroid, convalescent plasma | yes | low-risk | no | segmental | 8 | no | no | yes | 10 months | DOAC | no | no | partial |
6 | male | 42 | oxygen | vitamin D | no | low-risk | no | segmental | 1 | no | no | no | 6 months | DOAC | no | no | full |
7 | female | 50 | oxygen | no | no | low-risk | no | segmental | 13 | no | no | no | 6 months | DOAC | no | no | full |
8 | female | 77 | NIV | steroid, convalescent plasma | yes | high-risk | yes | segmental | 9 | no | no | yes | 6 months | DOAC | no | no | partial |
9 | male | 79 | NIV | steroid, convalescent plasma | no | intermediate-low-risk | no | segmental | 16 | no | no | no | 6 months | DOAC | no | no | full |
10 | female | 87 | oxygen | vitamin D | no | low-risk | no | segmental | 1 | yes | no | yes | 6 months | DOAC | no | no | partial |
11 | female | 36 | oxygen | no | no | intermediate-low-risk | no | segmental | 1 | no | no | no | 6 months | DOAC | no | no | full |
12 | male | 62 | oxygen | no | no | low-risk | no | segmental | 2 | no | no | no | 6 months | DOAC | no | no | full |
13 | female | 56 | none | no | no | low-risk | no | segmental | - | no | no | no | 6 months | DOAC | no | no | full |
14 | male | 46 | oxygen | steroid | no | intermediate-low-risk | no | segmental | 5 | no | no | no | 6 months | DOAC | no | no | full |
15 | male | 47 | oxygen | no | no | low-risk | no | segmental | - | no | no | yes | 3 months | DOAC | no | no | partial |
16 | female | 71 | oxygen | no | no | intermediate-high-risk | no | central | 17 | yes | no | no | 6 months | DOAC | no | no | full |
17 | male | 63 | NIV | convalescent plasma | yes | low-risk | no | segmental | - | no | no | no | 10 months | DOAC | no | no | full |
18 | female | 55 | oxygen | no | no | intermediate-low-risk | no | segmental | 27 | no | no | no | 6 months | DOAC | no | no | partial |
19 | male | 49 | oxygen | steroid | no | intermediate-low-risk | no | segmental | 8 | no | no | no | 4 months | DOAC | no | no | full |
20 | male | 54 | High-flow oxygen | remdesivir, steroid | no | Intermediate-high-risk | no | segmental | 12 | no | no | no | 3 months | DOAC | no | no | full |